FB

Meta Platforms, Inc.

196.64
USD
0.51%
196.64
USD
0.51%
169.00 384.33
52 weeks
52 weeks

Mkt Cap 465.31B

Shares Out 2.37B

Chat
Send me real-time posts from this site at my email

Innovent : Phase 2 Study Of Picankibart In Chinese Patients With Psoriasis Meets Primary Goal

(RTTNews) - Innovent Biologics Inc. (IVBXF.OB) said that a phase 2 study of picankibart in Chinese patients with moderate-to-severe plaque psoriasis met primary endpoint. Picankibart is a recombinant anti-interleukin 23p19 subunit antibody injection. A total of 250 subjects were randomized 1:1:1:1:1 to receive 50 mg (once at week 0, 4, then every 12 weeks), 100mg (once at week 0, 4, then every 12 weeks), 100mg (once at week 0, 4, then every 8 weeks), 200mg (once at week 0, 4, then every 12 weeks) of picankibart or placebo. To date, a total of 245 subjects (98.0%) have completed the primary endpoint at week 16, and a total of 236 subjects (94.4%) have completed the visit at week 28. Clinical study results showed that 50-200mg picankibart administered every 12 or 8 weeks significantly improved the skin lesions and quality of life of subjects with moderate to severe plaque psoriasis, demonstrating the significant improvement effect at long-dose interval. For More Such Health News, visit rttnews.com. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue